SYK STRYKER CORPORATION

Stryker announces intention to nominate Manny Maceda to board of directors

Stryker announces intention to nominate Manny Maceda to board of directors

Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025.

Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and CEO from 2018 to 2024. In that role, he led Bain’s global strategy and operations across more than 50 offices, driving the firm’s transformation to strengthen digital capabilities, expand its focus on sustainability, and preserve its award-winning culture.

Since joining Bain in 1989, Maceda has held multiple senior leadership roles and advised CEOs across a wide range of industries on enterprise-wide initiatives spanning strategy, growth, cost management, and organizational effectiveness.

He holds a Master of Science in Management from the MIT Sloan School of Management where he serves on the advisory board, and a bachelor’s degree in chemical engineering, with High Honors, from the Illinois Institute of Technology.

“We look forward to the potential of adding Manny to our Board,” said Kevin Lobo, Chair and CEO, Stryker. “His strategic acumen, global leadership experience and track record in transformation will enhance the Board as we grow, evolve and create long-term value for shareholders.”

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at .

Contacts

For investor inquiries:

Jason Beach, Vice President, Investor Relations at 269-385-2600 or  

For media inquiries:

Kim Montagnino, Vice President, Global Communications at 269-385-2600

or



EN
26/03/2025

Underlying

SYKSTRYKER CORPORATION

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRYKER CORPORATION

Free Trial
SYK STRYKER CORPORA...

Stryker Corp: 1 director

A director at Stryker Corp sold 500,000 shares at 363.439USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

SYK STRYKER CORPORATION
02/09/26 February 9, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services i...

February 4, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker reports 2025 operating results and 2026 outlook

Stryker reports 2025 operating results and 2026 outlook Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47  Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitio...

January 29, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker to announce financial results for its fourth quarter and full ...

Stryker to announce financial results for its fourth quarter and full year 2025 Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026.  A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, January 29, 2026, to discuss its fo...

January 5, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch